Targeting HIF-1α with Specific DNA Yokes for Effective Anticancer Therapy

Area of Science:

• Nanomedicine
• Molecular Biology
• Cancer Research

Background:

• Hypoxia is a key characteristic of solid tumors, driving cancer progression and therapeutic resistance.
• Hypoxia-inducible factor 1-alpha (HIF-1α) is a master transcriptional regulator of the hypoxic response and a critical therapeutic target in oncology.

Purpose of the Study:

• To introduce DNA yokes, a novel class of DNA nanopharmaceuticals, for targeting HIF-1α in cancer therapy.
• To evaluate the stability, intracellular behavior, and therapeutic efficacy of DNA yokes in vitro and in vivo.

Main Methods:

• Design and synthesis of DNA yokes, featuring a tetrahedral DNA nanostructure with hypoxia response elements (HREs).
• In vitro assessment of DNA yoke binding to HIF-1α, disruption of HIF-1α-DNA interactions, and induction of HIF-1α degradation via ubiquitination.
• Evaluation of DNA yokes' effects on cancer cell proliferation, migration, and invasion under hypoxic conditions.
• In vivo studies to assess tumor accumulation, tumor growth inhibition, and metastasis suppression.

Main Results:

• DNA yokes demonstrated high stability and prolonged intracellular retention.
• DNA yokes effectively bound HIF-1α, inhibited its transcriptional activity, and promoted its degradation.
• DNA yokes significantly attenuated cancer cell proliferation, migration, and invasion under hypoxia.
• Preferential accumulation of DNA yokes in tumors led to inhibited tumor growth and metastasis in vivo.

Conclusions:

• DNA yokes represent a promising new class of DNA-based nanopharmaceuticals for cancer therapy.
• The developed DNA yokes exhibit high stability, low toxicity to normal cells, and potent anti-cancer effects by targeting the HIF-1α pathway.